Gland Pharma Limited has announced a robust performance for the financial year ended March 31, 2026. The company achieved a consolidated revenue of ₹64,307 million, marking a 14% year-on-year growth. Following this strong financial year, the Board of Directors has recommended a final dividend of ₹20 per share. The annual results reflect significant progress across its diverse business segments, including strong growth in its contract development and manufacturing (CDMO) partnerships.
Fiscal Year 2026 Financial Performance
Gland Pharma has demonstrated significant financial momentum, reporting a consolidated annual revenue of ₹64,307 million for the fiscal year 2025-26, representing a 14% growth compared to the previous year. The company’s adjusted PAT for the same period stood at ₹10,455 million, a solid 50% increase year-on-year. For the fourth quarter (January-March), the company achieved revenues of ₹17,428 million, a 22% increase compared to the same quarter in the previous year.
Dividend and Annual Meeting
In recognition of the strong financial results, the Board has recommended a final dividend of ₹20 per equity share (representing 2000% of the face value of ₹1) for the 2025-26 financial year. The record date for determining shareholder eligibility for this dividend is set for Tuesday, August 11, 2026. The company’s 48th Annual General Meeting is scheduled to take place on Tuesday, August 25, 2026, via video conferencing.
Operational and Strategic Highlights
The company continues to strengthen its global footprint, with the CDMO business contributing 46% to the total revenue for the year, reflecting a 28% year-on-year growth. Key strategic milestones during the year included the launch of 31 new products in the USA and the filing of 24 new ANDAs. Furthermore, the company has expanded its capabilities with the introduction of new complex injectable products and maintained focus on its Ready-to-Use (RTU) bag portfolio, which addresses a significant market opportunity in the U.S.
Segment Focus: Cenexi
The Cenexi business segment reported annual revenue of €182 million (₹18,693 million), showcasing a 25% year-on-year growth. The performance was supported by increased capacity utilization and the successful ramp-up of two new products launched in 2025, specifically an inactivated vaccine and a sterile ophthalmic gel. Moving forward, the company plans to further enhance its European manufacturing capabilities with a new high-capacity ampoule filling line expected by August 2026.
Source: BSE
